HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports Increased Engagement as Canadian Facilities Reassess Compliance Exposure Ahead of Carbon Deadlines6.5.2026 15:15:00 CEST | Press release
170% year-over-year increase in traded volumes across TIER and BC OBPS within Karbon-X's trading activity reflects accelerated procurement activity as regulated entities enter the execution phase of the 2026 compliance cycle. CALGARY, AB / ACCESS Newswire / May 6, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today reported increased engagement from regulated facilities across Canada as organizations reassess their compliance position ahead of upcoming reporting and credit surrender deadlines. This includes a 170% increase in traded volumes across TIER and BC OBPS markets within Karbon-X's trading activity compared to the prior year, reflecting increased participation as facilities move into active procurement and execution phases ahead of submission timelines. As the current compliance cycle progresses across Alberta's Technology Innovation and Emissions Red
Global Sports Brand U.S. Polo Assn. Delivers Record $2.7 Billion in Retail Sales for 2025, Targets $4 Billion and 1,500 U.S. Polo Assn. Stores6.5.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / May 6, 2026 / USPA Global, the company that manages U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), today announced that the global sports brand has delivered a record $2.7 billion in worldwide retail sales in 2025, reflecting strong momentum across global markets, channels, and product categories. U.S. Polo Assn. is advancing toward a long‑term goal of $4 billion in global retail sales and 1,500 branded stores worldwide. Record Growth and Global Momentum U.S. Polo Assn.'s 2025 record-breaking performance was driven by continued expansion across both established and emerging markets. North America, the brand's largest region, delivered steady gains, while strong momentum continued across India, the Middle East, Western Europe, and Latin America. Emerging regions, including Asia Pacific and Eastern Europe, also contributed to meaningful growth for the global multi-billion-dollar brand. India remains the bra
Case IQ Advances Its Leadership Position in AI For Investigations with Playbooks6.5.2026 10:00:00 CEST | Press release
Playbooks is a new way to guide AI toward investigative outcomes that ethics, compliance, and HR teams across the EU can trust. LONDON, GB / ACCESS Newswire / May 6, 2026 / Case IQ, the leading provider of end-to-end compliance and risk management solutions for ethics, compliance and HR teams, today announced Playbooks, a new enhancement to Clairia, its AI assistant purpose-built for investigators. Case IQ continues to raise the bar for AI in investigations with Playbooks, which brings greater consistency, control, and confidence to AI-assisted case management. Playbooks enable organizations to shape how AI supports investigators based on their own standards, policies, and operational needs. Organizations feel pressure to adopt AI for investigations, making it difficult to govern, especially while navigating different regulations and standards across EU regions/countries. It's no surprise, as AI adoption is rising: according to our recent investigative benchmark report, which surveyed
Transoft Solutions Acquires CADaptor Solutions6.5.2026 08:00:00 CEST | Press release
Transoft Solutions Expands Temporary Traffic Management Portfolio With Latest Acquisition VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Transoft Solutions, a global leader in transportation engineering, analysis, and operations software, is pleased to announce that it has acquired CADaptor Solutions Ltd, developers of temporary traffic management software. CADaptor Solutions is based out of Huddersfield, UK and was established over 30 years ago. Their CONE Software solution is used widely in the United Kingdom within the Traffic Management industry to aid in the preparation of temporary traffic control diagrams, route diversion and event management schemes. CONE covers all aspects of temporary traffic management design from simple pedestrian footways through to complex multi-lane highway closures and contra-flows. It is used by wide variety of traffic planning related professionals including Highways Agencies, Utility Companies, Local Government, Traffic Management Companies, Civil E
Lawline Exits Beta and Launches Full AI Legal Platform for Businesses and Individuals5.5.2026 15:00:00 CEST | Press release
Sweden's most visited legal platform, recognised among the Nordics' top 9 AI legal startups alongside Legora and others, moves out of beta after surpassing 7,000 registered users, expanding its offering for companies, organisations, and individuals. STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Lawline, Sweden's most visited legal platform, today announced the official launch of its AI-driven legal platform, marking its transition out of beta. The launch introduces a significantly expanded product offering aimed at businesses, organisations, and individuals seeking accessible, reliable legal support in everyday decision-making. Lawline AI was first released in beta in February 2026 and has since attracted more than 7,000 registered users. With today's full launch, Lawline introduces a broader suite of capabilities designed to bring legal support closer to where decisions are actually made. "Legal support has traditionally been something you access after the fact, often when problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom